1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024

EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024

  • December 2015
  • 68 pages
  • ID: 3565275
In this report:
IT IS ALSO WIDELY STATED IN THE LITERATURE THAT SSC IS MORE PREVALENT IN WOMEN THAN MEN, AND GLOBALDATA EPIDEMIOLOGISTS FOUND THIS TO BE TRUE ACROSS ALL OF THE ##MM, WITH ESTIMATES OF THE PROPORTION OF CASES IN WOMEN RANGING FROM ##.##% IN THE US TO ##.##% IN JAPAN (MAYES ET AL., 2003; TAMAKI ET AL., 1991).
IN THE ##MM, GLOBALDATA EPIDEMIOLOGISTS FORECAST THAT THE DIAGNOSED PREVALENT CASES OF SSC FOR AGES ## YEARS AND OLDER WILL INCREASE FROM ##,## DIAGNOSED PREVALENT CASES IN 2014 TO ##,## DIAGNOSED PREVALENT CASES IN 2024, AT AN ANNUAL GROWTH RATE (AGR) OF ##.##% DURING THE FORECAST PERIOD.

Summary

Table of Contents

Search Inside

EpiCast Report: Systemic Sclerosis - Epidemiology Forecast to 2024

Brief

Systemic sclerosis is an autoimmune disease of the connective tissue, and is characterized by excessive fibrosis, vascular alterations, and the proliferation of antibodies against numerous cellular antigens. SSc primarily affects those ages 40-50 years, and occurs predominantly in women, with a female-to-male sex ratio of 4:1. There are two principal forms of the disease: limited and diffuse cutaneous scleroderma (lSSc and dSSc, respectively). lSSc primarily affects the hands, arms, and face, whereas dSSc affects a vast area of the skin and involves one or more internal organs. Raynaud's phenomenon develops in the majority of both forms of SSc. The primary cause of death in both lSSC and dSSc is involvement of the lungs.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of SSc for ages 18 years and older will increase from 131,129 cases in 2014 to 141,499 cases in 2024. GlobalData epidemiologists forecast that in 2024, the U.S. will have the more significant number of diagnosed prevalent cases of SSc, with 95,992 cases, accounting for 68.0 percent of cases in the 7MM. In the 7MM in 2014, the group age 50-59 years had the more important proportion of diagnosed prevalent cases of SSc at ~25.5 percent. In 2014, the diagnosed prevalent cases of SSc in the 7MM were lower in men compared with women with ~15.4 percent diagnosed prevalent cases in men and ~84.6 percent diagnosed prevalent cases in women. Of all the diagnosed prevalent cases of SSc in the 7MM in 2014, more had experienced RP (126,151 cases) than a DU (67,099 cases). In each of the 7MM, approximately 95.0 percent of the diagnosed prevalent SSc cases had experienced RP. In all markets other than France, Germany (DE), and Italy (IT), ~70.5 percent of the diagnosed prevalent cases of SSc were lSSc. In the 7MM in 2014, 18,395 of the diagnosed prevalent cases of dSSc had ILD, and 6,679 of the diagnosed prevalent cases of dSSc had kidney disease.

GlobalData epidemiologists utilized exhaustive, country-specific data from registries and peer-reviewed journal articles to arrive at a meaningful, exhaustive analysis and estimate for the diagnosed prevalent cases of SSc. In this analysis, GlobalData epidemiologists provide in-depth, clinically efficient segmentations for the diagnosed prevalent cases of SSc. Finally, the same forecast methodology was used across the 7MM, thereby allowing for meaningful overall comparisons of the diagnosed prevalent cases of SSc across these markets.

Overview

- The Systemic Sclerosis EpiCast Report offers an overview of the risk factors and overall trends of SSc in the 7MM (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)). It includes a 10-year epidemiology forecast of SSc diagnosed prevalent cases in these markets, divided by age, sex, presence of Raynaud's phenomenon, presence of digital ulcers, limited systemic sclerosis, and diffuse systemic sclerosis. The diagnosed prevalent cases of dSSc are farther broken down into cases with pulmonary fibrosis /interstitial lung disease and kidney disease.

- The SSc epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is detailed, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Great reasons to purchase

The SSc EpiCast report will allow you to -

- Develop strategic management by understanding the trends shaping and driving the overall SSc market.

- Quantify patient populations in the overall SSc market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SSc therapeutics in each of the markets covered.

- Identify the percentage of SSc diagnosed prevalent cases by disease type.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Polycystic Kidney Disease Global Clinical Trials Review, H1, 2018

Clinical Research in Polycystic Kidney Disease in H1, 2018

  • $ 2500
  • Industry report
  • May 2018
  • by GlobalData

Polycystic Kidney Disease Global Clinical Trials Review, H1, 2018SummaryGlobalData’s clinical trial report, “Polycystic Kidney Disease Global Clinical Trials Review, H1, 2018" provides an overview ...

Polycystic Kidney Disease R&D Pipeline Analysis Report, H2-2018

Polycystic Kidney Disease R&D Pipeline Analysis Report, H2-2018

  • $ 2200
  • Industry report
  • August 2018
  • by VPAResearch

Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studiesPolycystic Kidney Disease Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information ...

End Stage Renal Disease (ESRD) R&D Pipeline Analysis Report, H2-2018

End Stage Renal Disease (ESRD) R&D Pipeline Analysis Report, H2-2018

  • $ 2200
  • Industry report
  • August 2018
  • by VPAResearch

Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studiesEnd Stage Renal Disease (ESRD) Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on